This clinical trial is focused on studying the effects of a medication called Jardiance on individuals who have received a kidney transplant. Jardiance contains the active ingredient empagliflozin, which is a type of medication known as an SGLT2 inhibitor. The purpose of the study is to evaluate how Jardiance affects the oxygen levels in the transplanted kidney. Participants in the study will either receive Jardiance or a placebo, which looks like the medication but does not contain any active ingredients.

The study will involve kidney transplant recipients who are not diabetic and have had their transplant for more than six months. Participants will be monitored to see how Jardiance affects the oxygen levels in different parts of the kidney, specifically the cortex and medulla, which are areas within the kidney. This will be done using a special imaging technique called MRI, which allows doctors to see inside the body without surgery. The study will also look at other factors such as blood flow to the kidney, blood sugar levels, blood pressure, and heart rate.

The trial is designed to be a crossover study, meaning that participants will receive both the medication and the placebo at different times during the study. This helps researchers compare the effects of the medication directly with the placebo. The study is expected to start recruiting participants in early 2025 and will continue until 2027. The findings from this study could provide valuable insights into how Jardiance affects kidney function in transplant recipients.